In The News

In The News

65 Results found
65 Results found

Waldencast Announces Q2 2025 Results and Provides Q3 2025 Trading Update

Obagi Medical Shares New Clinical Data on Obagi Hyaluronic Acid Injectables and Nu-Cil Scalp Serum at the 2025 American Society for Dermatologic Surgery Annual Meeting

Waldencast plc strengthens balance sheet position with the announcement of a trademark sale for Japan and refinancing of its credit facilities

Waldencast plc Provides Information Regarding Upcoming Earnings Release Dates

Obagi Medical Launches Nu-Cil® BioStim™ Scalp Serum

Waldencast Announces FDA Approval of Obagi® saypha® MagIQ™ Injectable Hyaluronic Acid Gel Under the Obagi Medical Brand

Waldencast Announces Strong Progress on Business Priorities for H1 2025 and Initiatives to Drive Transformation

Waldencast Acquires Novaestiq Corp. and U.S. Rights to Leading Injectable Hyaluronic Acid Gel Line, Saypha®, Under the Obagi Medical Brand